<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159627</url>
  </required_header>
  <id_info>
    <org_study_id>CKI-202</org_study_id>
    <nct_id>NCT00159627</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Effects of KW-3902 on Diuresis in Patients With Congestive Heart Failure (CHF) Refractory to High Dose Diuretic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaCardia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NovaCardia, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to&#xD;
      determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with&#xD;
      volume overload due to CHF who are refractory to high dose diuretic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urine volume from baseline</measure>
  </primary_outcome>
  <enrollment>52</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-3902IV</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of CHF for greater than 3 months,&#xD;
&#xD;
          -  Receiving oral/IV diuretic therapy&#xD;
&#xD;
          -  Hospitalized for therapy for HF and edema that has not responded to diuretic therapy.&#xD;
&#xD;
          -  Signs and symptoms of ongoing volume overload&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction in past 14 days&#xD;
&#xD;
          -  Clinical evidence of acute coronary syndrome causing worsening of HF,&#xD;
&#xD;
          -  Pregnant or breast-feeding,&#xD;
&#xD;
          -  Severe, uncorrected primary valvular disease, constrictive pericarditis, restrictive&#xD;
             or hypertrophic cardiomyopathy,&#xD;
&#xD;
          -  Automated implanted cardiac defibrillator (AICD) or synchronization device implanted&#xD;
             within the preceding 7 days,&#xD;
&#xD;
          -  Require mechanical ventilation, ultrafiltration, or hemodialysis at the time of&#xD;
             enrollment,&#xD;
&#xD;
          -  Deterioration due to an acute or superimposed condition requiring therapy other than&#xD;
             diuretics&#xD;
&#xD;
          -  Symptomatic ventricular tachycardia,&#xD;
&#xD;
          -  Severe concomitant primary hepatic disease,&#xD;
&#xD;
          -  Severe pulmonary disease,&#xD;
&#xD;
          -  Any other concomitant life-threatening disease,&#xD;
&#xD;
          -  CVA in the preceding 6 months,&#xD;
&#xD;
          -  Hypotension,&#xD;
&#xD;
          -  Participated in another clinical trial within 30 days,&#xD;
&#xD;
          -  Acute contrast nephropathy,&#xD;
&#xD;
          -  Admitted for heart transplant surgery or have had a heart transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ayer</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>January 28, 2008</last_update_submitted>
  <last_update_submitted_qc>January 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2008</last_update_posted>
  <keyword>heart failure, congestive</keyword>
  <keyword>diuretic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rolofylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

